ALS Center Leuven

UZ Leuven

The Leuven ALS center combines the diagnosis and multidisciplinary care for ALS and ALS/FTLD patients with clinical and basic research activities.

Leuven_logo's
UZ Leuven

Clinical research activities include genetic, imaging, electrophysiological and biomarker studies, as well as phase I-III clinical trials (P. Van Damme, MD, PhD). Basic research activities include generation of small animal models, rodent models and stem cell models for ALS and FTLD, and use them to identify and validate molecular targets for the treatment of these diseases (W. Robberecht MD, PhD, P. Van Damme, MD, PhD, and L. Van Den Bosch, PhD).

Contact
Location
Herestraat 49, 3000 Leuven, Belgium

Specialists

Philip van Damme

Professor of Neurology

Professor Philip van Damme is professor of Neurology at the UZ Leuven in Belgium

Philip van Damme
Current trials
Recruiting
Phase iii

TUDCA-ALS (TUDCA)

Industry sponsored trial

TUDCA (tauroursodeoxycholic acid) is a small molecule that is being explored for its potential as a treatment for ALS

Read more
In preparation
Phase iii

PreLude (Lithium carbonate)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of lithium carbonate in UNC13a homozygous patients.

Read more
In preparation
Phase ii

Lighthouse (Triumeq)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of Triumeq, a therapy developed for treatment of HIV that has shown to slow progression in ALS

Read more
In preparation
Phase iii

iAdore (Oral edaravone)

Platform trial arm

Within an innovative platform design study, we will evaluate the efficacy of oral edaravone (TW001), a formulation that reduces oxidative stress

Read more